Tricyclic compounds as inhibitors of mutant IDH enzymes

US10442819B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Christian Fischer · Natick, US
• Stephane L. Bogen · Somerville, US
• Matthew L. Childers · Medfield, US
• Francesc Xavier Fradera Llinas · Brookline, US
• J. Michael Ellis · Needham, US
• Sara Esposite · Neptune, US
• Qingmei Hong · Scotch Plains, US
• Chunhui Huang · Arlington, US
• Alexander Kim · Levittown, US
• John W. Lampe · Orange, US
• Michelle R. Machacek · Brookline, US
• Daniel R. McMasters · Brookline, US
• Ryan D. Otte · Natick, US
• Dann Parker · Cranford, US
• Michael H. Reutershan · Watertown, US
• Nunzio Sciammetta · Sudbury, US
• Pengcheng Patrick Shao · Fanwood, US
• David L. Sloman · Brookline, US
• Feroze Ujjainwalla · Hoboken, US
• Catherine White · Newton, US
• Zhicai Wu · Montvale, US
• Yang Yu · Jinan, CN
• Kake Zhao · Westfield, US
• Craig R. Gibeau · Holliston, US
• Tesfaye Biftu · Belmont, US
• Purakkattle Biju · Piscataway, US
• Lei Chen · Singapore, SG
• Joshua Close · Franklin, US
• Peter H. Fuller · Ashland, US
• Xianhai Huang · Hackettstown, US

Key dates

• Filing date: Dec 1, 2015
• Grant date: Oct 15, 2019
• Expiry date: Dec 1, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A01N43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.